Physician profile
Mark Levitan
NPI 1609848399
$38,879.62
in general payments reported to CMS, 2019-2025
16 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $382 · 2021: $435 · 2022: $3,929 · 2023: $32K · 2024: $995 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $32K · Food and Beverage: $989 · Grant: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $32,166.50 |
| Food and Beverage | $988.85 |
| Grant | $500.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $32,471.50 | 2022-2023 | Hillrom - Retinavue 700 Imager, Hillrom - Retinavue Network |
| US Retina LLC | $4,331.07 | 2019-2022 | |
| Abbvie INC. | $500.15 | 2024 | |
| Harrow Eye, LLC | $364.58 | 2024 | Iheezo |
| Novartis Pharmaceuticals Corporation | $259.15 | 2019-2022 | |
| Genentech USA, INC. | $204.83 | 2019-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $190.44 | 2023-2025 | Eylea Hd, Eylea |
| Carl Zeiss Meditec, INC. | $175.63 | 2020 | |
| Astellas Pharma US INC | $175.05 | 2023-2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $61.80 | 2025 | Syfovre |
| Acist Medical Systems, INC. | $45.00 | 2021 | |
| Ani Pharmaceuticals, INC. | $29.20 | 2025 | Iluvien |
| Neurotech Pharmaceuticals, INC. | $25.82 | 2025 | |
| Alimera Sciences, INC. | $19.66 | 2022 | |
| Mallinckrodt Hospital Products INC. | $15.94 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $9.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,285.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Levitan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.